Introduction {#cei13283-sec-0001}
============

Metastatic melanoma (MM) often affects younger people and is the most devastating form of cancer regarding life‐years lost. Dacarbazine (DTIC) has traditionally been the standard therapeutic drug for patients with MM, but the response rates are low (approximately 10%), and the effect not sustained [1](#cei13283-bib-0001){ref-type="ref"}. In Europe, until 2011 no new drugs had been approved for the treatment of MM for more than 30 years. Since then new therapeutic approaches have been authorized, including immunotherapy with ipilimumab (anti‐CTLA‐4 antibody), as well as nivolumab and pembrolizumab \[programmed cell death 1 (PD)‐1 inhibitors\] and the combination of ipilimumab and nivolumab, resulting in improved overall survival [2](#cei13283-bib-0002){ref-type="ref"}, [3](#cei13283-bib-0003){ref-type="ref"}, [4](#cei13283-bib-0004){ref-type="ref"}, [5](#cei13283-bib-0005){ref-type="ref"}, [6](#cei13283-bib-0006){ref-type="ref"}, [7](#cei13283-bib-0007){ref-type="ref"}, [8](#cei13283-bib-0008){ref-type="ref"}. At present, the first line of systemic immunotherapy for MM includes ipilimumab/nivolumab combination or nivolumab or pembrolizumab alone. Second‐line treatment depends on the choice in the first line, but includes ipilimumab, and PD‐1 inhibitors only or in combination with other new immune checkpoint inhibitors in clinical trials. At present, however, immunotherapies in MM lack prognostic biomarkers. As these therapeutic options also have serious side effects, markers could help to select patients that will be in particular benefit of such therapy.

Overcoming tumor immune tolerance can be induced by monoclonal antibodies (mAbs) blocking negative signaling receptors, such as cytotoxic T lymphocyte antigen 4 (CTLA‐4), which is a central regulation mechanism for T cell activation. Ipilimumab is a human CTLA‐4 mAb that blocks the interaction with its ligands CD80/CD86, and can lead to long‐lasting anti‐tumor effects and disease control. In MM, approximately 20% of patients experience long‐term survival after treatment with ipilimumab [4](#cei13283-bib-0004){ref-type="ref"}, [9](#cei13283-bib-0009){ref-type="ref"}, but 20--27% of patients treated develop serious side effects (grades 3--4) [10](#cei13283-bib-0010){ref-type="ref"}. Access to biomarkers defining patients likely to respond and survive has been long awaited [11](#cei13283-bib-0011){ref-type="ref"}.

The development and progression of MM are characterized by chronic inflammation [12](#cei13283-bib-0012){ref-type="ref"}, [13](#cei13283-bib-0013){ref-type="ref"} which has been recognized as a driving force for both epidermal cell transformation as well as malignant progression. Thus, a wide range of inflammatory and related mediators, including cytokines, chemokines, regulators of the extracellular matrix (ECM), reactive oxygen species and angiogenic factors, are present in the tumor microenvironment. Such factors may be derived from infiltrating inflammatory cells and/or from the tumor cells or interactions between these cells, and may influence the rate of tumor progression and the outcome of cancer treatment [14](#cei13283-bib-0014){ref-type="ref"}. These inflammatory mediators may be quantified in the circulation and utilized as biomarkers [11](#cei13283-bib-0011){ref-type="ref"}, [15](#cei13283-bib-0015){ref-type="ref"}, [16](#cei13283-bib-0016){ref-type="ref"}, [17](#cei13283-bib-0017){ref-type="ref"}. Thus, whereas MM in itself is associated with enhanced inflammation, immunotherapy such as ipilimumab will further activate certain inflammatory pathways. To characterize the inflammatory phenotype in MM as well as how this phenotype changes during successful ipilimumab therapy may be of major importance to selected patients who will benefit from such treatment.

Based on these issues, we examined markers reflecting different inflammatory pathways that could give novel information on prognosis during immunotherapy (i.e. ipilimumab) in MM. We selected markers on the basis that they reflected activation of pathways that are relevant for melanoma progression [18](#cei13283-bib-0018){ref-type="ref"} as well as the effects of ipilimumab [19](#cei13283-bib-0019){ref-type="ref"}. Against this background we examined general downstream markers of inflammation \[i.e. C‐reactive protein (CRP), soluble tumor necrosis factor receptor type 1 (sTNFR1)\], markers of endothelial cell activation and vascular inflammation \[i.e. pentraxin 3 (PTX3), osteoprotegerin (OPG), von Willebrand factor (vWF), the chemokine CXCL16 and the notch ligand delta‐like 1 (DLL1)\], angiogenetic factors \[i.e. Axl, endothelial cell protein C receptor (ePCR) and endostatin\], markers related to fibrosis and extracellular matrix (ECM) remodeling \[i.e. growth differentiation factor 15 (GDF‐15), galectin 3 binding protein (Gal3BP), cathepsin S (CatS/CD147)\] and markers reflecting monocyte/macrophage activation \[the chemokine CCL18 and the soluble (s) markers sCD163 and activated leukocyte cell adhesion molecule (ALCAM)/sCD166\]) at three time‐points in melanoma patients treated with ipilimumab and evaluated their association with 2 years' survival. As this were non‐randomized real‐world data, the identified markers could only be assigned prognostic value on ipilimumab treatment rather than being of predictive value for response to ipilimumab therapy.

Materials and methods {#cei13283-sec-0002}
=====================

Patient population {#cei13283-sec-0003}
------------------

From January 2014 to March 2015, 69 patients with unresectable or metastatic malignant melanoma were included and started treatment with ipilimumab as part of a national Phase IV study (NCT0268196/EudraCT2013‐002408‐15) at the Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital. The patients received treatment with up to four doses of ipilimumab 3 mg/kg intravenously every third week. Six patients had ≤ two doses of ipilimumab due to very rapid disease progression, eight patients had three courses due to high‐grade side effects, and the remainder had all four doses as planned. A total number of 56 patients from whom fresh‐frozen serum samples were obtained at baseline (before the start of treatment), week 4 (before the second treatment) and/or week 7 (before the third treatment) were included in this substudy. The 13 patients who were not reported were due to screening failure (four patients) and lack of blood tests taken (nine patients). Thus, none of the patients who were not reported showed rapid deterioration during follow‐up. The patients started therapy on week 1 and were followed‐up every third week during treatment. They had the first computerized tomography (CT) scan for evaluation at week 12, and the next scan at week 16 to evaluate pseudoprogression. Further regular visits and CT scans were at week 24 and every third month after that for 3 years or until progression. The study was approved by the regional ethics committee and conducted by the Declaration of Helsinki. All patients gave written informed consent to participate in the study.

Blood sampling and biochemical analyses {#cei13283-sec-0004}
---------------------------------------

Peripheral venous blood was drawn into pyrogen‐free tubes without any additives. After coagulation at room temperature, tubes were centrifuged at 1500 ***g*** for 10 min, and serum was stored at --80°C in multiple aliquots. Serum levels of CRP (Cat. no. DY1707), PTX3 (Cat. no. DY1826), sTNFR1 (Cat. no. DY225), OPG (Cat. no. DY805), DLL1 (Cat. no. DY1818), CXCL16 (Cat. no. DY1164), Axl (Cat. no. DY154), ePCR (Cat. no. DY2245), endostatin (Cat. no. DY1098), GDF‐15 (Cat. no. DY957), CatS (Cat. no. DY1183), CD147 (Cat. no. DY972), CCL18 (Cat. no. DY394), Gal3BP (Cat. no. DY2226), sCD163 (Cat. no. DY1607) and sCD166 (Cat. no. DY656) were measured in duplicate by enzyme‐linked immunosorbent assay with antibodies obtained from R&D Systems (Minneapolis, MN, USA) in a 384 format using a combination of a CyBi SELMA (CyBio, Jena, Germany), EL406 washer/dispenser (Biotek, Winooski, VT, USA) and Synergy H2 microplate reader (Biotek). vWF was measured by the same method with antibodies obtained from DakoCytomation (Glostrup, Denmark). The intra‐ and interindividual coefficients of variation were \<10%.

Statistical analysis {#cei13283-sec-0005}
--------------------

As the inflammatory markers were skewed, data were analyzed using the Mann--Whitney *U*‐test and χ^2^ correlation. Receiver operating characteristic (ROC) curves of inflammatory markers at baseline were created, and the area under the curve (AUC) was used to evaluate the prognostic effect of each parameter. Where appropriate, Kaplan--Meier curved on dichotomized levels, multivariable logistic regression analysis and Cox proportional hazards regression \[adjusted for lactate dehydrogenase (LDH) levels, M stage and number of organs affected\] were performed in order to assess the relationship between inflammatory markers \[log‐transformed with hazard ratios expressed per standard deviation (s.d.) change\], clinical parameters and the outcome of survival after 2 years. Survival at 2 years was defined from trial inclusion. Two‐sided *P*‐values of \<0·05 were considered significant. [spss]{.smallcaps} version 23 software (IBM, Armonk, NY, USA) was used for all statistical analyses.

Results {#cei13283-sec-0006}
=======

Patient characteristics {#cei13283-sec-0007}
-----------------------

Table [1](#cei13283-tbl-0001){ref-type="table"} presents the baseline characteristics of the MM patient population according to survival status. Twenty‐three (41%) of the patients were alive and thirty‐three (59%) were dead 2 years after inclusion in the Phase IV study. All non‐survivors died from disease progression of melanoma. As expected, non‐survivors had a more advanced disease stage and higher LDH serum levels than survivors. Twelve of the survivors and thirteen of the non‐survivors had a BRAF V600 mutated tumor. Most patients had one or no systemic treatment before they were included in the study.

###### 

Clinical characteristics of the study population according to survival

  Total                                          Survival 2 years   
  ---------------------------------------------- ------------------ ---------------------------------------------------
                                                 23 (41)            33 (59)
  Gender                                                            
  Men                                            11 (20)            22 (39)
  Women                                          12 (21)            11 (20)
  Age, years, Median (range)                     60 (27--83)        67 (38--84)
  M stage M1a/b                                  9 (38)             4 (14)
  M1c                                            14 (62)            29 (86)[\*](#cei13283-note-0004){ref-type="fn"}
  Organs involved ≤ 2                            16 (29)            13 (23)
  \>2                                            7 (12)             20 (36)
  BRAF v600 Mutation, No                         8 (14)             17 (30)
  Yes                                            12 (21)            13 (23)
  Unknown                                        3 (5)              3 (5)
  LDH, normal                                    19 (34)            14 (25)
  \>ULN[†](#cei13283-note-0002){ref-type="fn"}   4 (7)              19 (34)[\*\*](#cei13283-note-0005){ref-type="fn"}
  Number of treatments before inclusion, 0       11 (20)            18 (32)
  1                                              9 (16)             13 (23)
  2                                              2 (4)              1 (1·7)
  3                                              1 (1·7)            1 (1·7)
  ANC[\#](#cei13283-note-0003){ref-type="fn"}    4·7 (1·7)          4·8 (1·4)
  AEC[\#](#cei13283-note-0003){ref-type="fn"}    0·1 (0·1)          0·1 (0·1)
  ALC[\#](#cei13283-note-0003){ref-type="fn"}    1·6 (0·5)          1·4 (0·6)
  Increase AEC                                   13 (57)            18 (55)
  Increase ALC                                   17 (74)            16 (49)
  irAE                                           8 (35)             15 (46)

Data are shown as number of patients (%) unless otherwise indicated.

ULN = upper limit of normal,

mean (standard deviation).

*P* \< 0·05;

*P* \< 0·01 *versus* survivors.

ANC = absolute neutrophil count (10^9^/l); AEC = absolute eosinophil count (10^9^/l); ALC = absolute lymphocyte count (10^9^/l); irAE = immune‐related adverse event; LDH = lactate dehydrogenase (U/l); M stage = metastatic stage (AJCC cancer staging manual).
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In contrast to what has been reported by others [20](#cei13283-bib-0020){ref-type="ref"}, [21](#cei13283-bib-0021){ref-type="ref"}, [22](#cei13283-bib-0022){ref-type="ref"}, [23](#cei13283-bib-0023){ref-type="ref"}, we found no correlation between peripheral blood biomarkers such as absolute neutrophil count (ANC), absolute eosinophil count (AEC), absolute lymphocyte count (ALC) or increase in AEC or ALC and outcome of ipilimumab treatment.

Patients included in this study had a broad spectrum and grade of different immune‐related side effects (irAE). However, the number of patients in our cohort was somewhat low (*n* = 56), and we therefore did not group the irAE according to grade or type of irAE in statistical analyses. When we included all irAE (grades 1--4) regularly registered during the treatment visits in the IPI4 study, we found no association between any immune‐related side effect and 2 years of survival.

Biomarkers during treatment {#cei13283-sec-0008}
---------------------------

Median and interquartile levels of the examined markers before treatment (i.e*.* baseline), at second treatment (i.e. 4 weeks) and at third treatment (i.e. 7 weeks) with ipilimumab are presented in Table [2](#cei13283-tbl-0002){ref-type="table"}. Several of the markers demonstrated higher levels in serum from non‐survivors compared to survivors at several time‐points, i.e. CRP, sTNFR1, PTX3, OPG, CXCL16, Axl, endostatin, GDF15, Gal3BP, CatS, CCL18/PARC and sCD163. Of these, CRP, endostatin, GDF15, OPG, PARC and Gal3BP were consistently elevated in non‐survivors at all time‐points and were therefore selected for further analyses.

###### 

Serum levels (quartiles) of biomarkers before and during treatment with ipilimumab stratified survival status

                                   Survival                                                   Baseline                                                    Week 4                                                      Week 7
  -------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -------------------
  Inflammation in general                                                                                                                                                                                             
  CRP (μg/ml)                      Alive                                                      0·8 (0·2, 2·3)                                              1·0 (0·5, 3·5)                                              1·5 (0·6, 3·5)
  Dead                             2·8 (1·4, 5·4)[\*\*](#cei13283-note-0008){ref-type="fn"}   4·8 (2·4, 6·4)[\*\*](#cei13283-note-0008){ref-type="fn"}    3·8 (2·5, 7·0)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  sTNF‐R1 (ng/ml)                  Alive                                                      2·2 (1·8, 2·6)                                              2·3 (2·0, 3·1)                                              2·5 (2·0, 2·8)
  Dead                             2·2 (1·9, 3·3)                                             3·2 (2·6, 4·7)[\*\*](#cei13283-note-0008){ref-type="fn"}    3·1 (2·5, 5·3)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  Vascular inflammation                                                                                                                                                                                               
  PTX3 (ng/ml)                     Alive                                                      1·1 (0·6, 1·7)                                              1·2 (0·6, 1·9)                                              1·3 (0·8, 1·9)
  Dead                             1·9 (1·0, 2·5)                                             2·3 (1·6, 3·6)[\*\*](#cei13283-note-0008){ref-type="fn"}    2·2 (1·4, 4·1)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  OPG (ng/ml)                      Alive                                                      3·5 (3·0, 4·5)                                              3·7 (2·9, 4·8)                                              3·8 (3·4, 5·0)
  Dead                             5·1 (3·8, 5·6)[\*\*](#cei13283-note-0008){ref-type="fn"}   5·5 (4·0, 6·5)[\*](#cei13283-note-0007){ref-type="fn"}      6·2 (4·2, 6·8)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  vWF (AU)                         Alive                                                      58 (48, 71)                                                 61 (51, 87)                                                 64 (37, 92)
  Dead                             68 (51, 87)                                                73 (59, 113)                                                65 (33, 126)                                                
  CXCL16 (ng/ml)                   Alive                                                      2·3 (2·1, 2·7)                                              2·4 (2·1, 2·8)                                              2·1 (2·0, 2·6)
  Dead                             2·7 (2·3, 3·3)                                             2·6 (2·2, 3·2)                                              2·7 (2·3, 3·1)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  DLL1 (ng/ml)                     Alive                                                      13·7 (11·3, 16·4)                                           14·8 (12·9, 20·0)                                           14·4 (12·1, 15·8)
  Dead                             13·6 (12·1, 15·9)                                          15·1(13·5, 17·8)                                            17·0 (12·9, 18·9)                                           
  Angiogenesis                                                                                                                                                                                                        
  Axl (ng/ml)                      Alive                                                      5·2 (4·1, 5·6)                                              5·2 (4·3, 5·7)                                              5·3 (4·5, 6·1)
  Dead                             5·3 (4·6, 6·4)                                             5·9 (5·4, 6·5)[\*\*](#cei13283-note-0008){ref-type="fn"}    6·0 (5·4, 8·6)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  ePCR (ng/ml)                     Alive                                                      33 (29, 43)                                                 32 (27, 39)                                                 33 (27, 38)
  Dead                             36 (28, 41)                                                35 (28, 41)                                                 37 (32, 43)                                                 
  Endostatin (ng/ml)               Alive                                                      134 (113, 154)                                              132 (114·5, 147·5)                                          133 (115, 162)
  Dead                             158 (137, 189)[\*](#cei13283-note-0007){ref-type="fn"}     170·5 (155, 202)[\*](#cei13283-note-0007){ref-type="fn"}    181 (148, 221)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  ECM/fibrosis                                                                                                                                                                                                        
  GDF15 (ng/ml)                    Alive                                                      0·4 (0·2, 0·7)                                              0·4 (0·3, 0·8)                                              0·4 (0·3, 0·8)
  Dead                             0·8 (0·4, 1·4)[\*\*](#cei13283-note-0008){ref-type="fn"}   0·7 (0·5, 2·0)[\*\*](#cei13283-note-0008){ref-type="fn"}    0·8 (0·5, 1·9)[\*\*](#cei13283-note-0008){ref-type="fn"}    
  Gal3BP/sCD166 (μg/ml)            Alive                                                      1·2 (0·8, 2·0)                                              1·3 (0·7, 2·4)                                              1·0 (0·9, 2·0)
  Dead                             2·0 (1·7, 3·1)[\*\*](#cei13283-note-0008){ref-type="fn"}   2·4 (1·7, 4·1)[\*\*](#cei13283-note-0008){ref-type="fn"}    2·7 (1·9, 3·4)[\*](#cei13283-note-0007){ref-type="fn"}      
  CatS (ng/ml)                     Alive                                                      53 (47, 61)                                                 56 (50, 61)                                                 55 (50, 59)
  Dead                             55 (51, 60)                                                56 (38, 62)                                                 60 (54, 67)[\*\*](#cei13283-note-0008){ref-type="fn"}       
  CD147 (ng/ml)                    Alive                                                      9·1 (7·3, 10·2)                                             9·4 (7·4, 11·1)                                             8·9 (7·4, 10·3)
  Dead                             8·7 (7·5, 10·0)                                            9·9 (8·2, 11·7)                                             10·1 (8·1, 12·4)                                            
  Monocyte/macrophage activation                                                                                                                                                                                      
  CCL18/PARC (ng/ml)               Alive                                                      65 (55, 88)                                                 79 (58, 102)                                                78 (68, 96)
  Dead                             102 (78, 115)[\*](#cei13283-note-0007){ref-type="fn"}      103 (78, 134)[\*\*](#cei13283-note-0008){ref-type="fn"}     115 (85, 155)[\*\*](#cei13283-note-0008){ref-type="fn"}     
  sCD163 (ng/ml)                   Alive                                                      421 (317, 690)                                              516 (353, 645)                                              562 (317, 699)
  Dead                             650 (494, 831)                                             824 (595, 1066)[\*\*](#cei13283-note-0008){ref-type="fn"}   865 (557, 1145)[\*\*](#cei13283-note-0008){ref-type="fn"}   
  Alcam/sCD166 (ng/ml)             Alive                                                      102 (92, 121)                                               107 (92, 112)                                               105 (97, 121)
  Dead                             101 (84, 115)                                              107 (89, 121)                                               102 (89, 131)                                               

*P* \< 0·05;

*P* \< 0·01 comparing non‐survivors and survivors.

CRP = C‐reactive protein; sTNF‐R1 = soluble tumor necrosis factor receptors; PTX3 = pentraxin‐related protein/TNF‐inducible gene 14 protein (TSG‐14); OPG = osteoprotegerin; vWF = Von Willebrand factor; ePCR = endothelial cell protein C receptor; CXCL = chemokine ligand; DLL1 = delta‐like protein 1; ECM = extracellular matrix; GDF15 = growth differentiation factor 15; Gal3BP = galectin‐3 binding‐protein/CYT‐MAA/K90/Mac‐2BP; CatS = cathepsin S; PARC = pulmonary and activation‐regulated chemokine.
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Baseline levels of inflammatory markers in relation to disease severity {#cei13283-sec-0009}
-----------------------------------------------------------------------

Of the six selected inflammatory markers, several were associated with different measures of disease severity, as shown in Table [3](#cei13283-tbl-0003){ref-type="table"}. First, significantly higher levels of GDF15, endostatin, PARC and CRP were observed in patients with more organs affected. Secondly, GDF15, Gal3BP and CRP were significantly higher in patients with stage M1c, reflecting a higher tumor burden. Similarly, OPG, GDF15, PARC and CRP levels were significantly higher in those with higher LDH as a marker of tissue damage, above the upper limit of normal individuals.

###### 

Serum levels quartiles of selected markers at start of treatment in relation to disease severity

                                                                                Organs involved                                                            M stage                                                                     LDH
  -------------------- -------------------------------------------------------- ----------------- -------------------------------------------------------- ---------------- ---------------------------------------------------------- ----------------
  OPG (ng/ml)          ≤2                                                       4·0 (3·4--4·6)    M1a/b                                                    3·7 (2·9--4·7)   Norm                                                       4·0 (3·4--4·6)
  \>2                  4·9 (4·2--5·7)                                           M1c               4·6 (4·1--5·2)                                           \>ULN            5·0 (4·3--6·0)[\*](#cei13283-note-0011){ref-type="fn"}     
  GDF15 (ng/ml)        ≤2                                                       0·5 (0·3--0·7)    M1a/b                                                    0·4 (0·2--0·7)   Norm                                                       0·4 (0·3--0·7)
  \>2                  1·0 (0·7--1·5)[\*](#cei13283-note-0011){ref-type="fn"}   M1c               0·8 (0·6--1·1)[\*](#cei13283-note-0011){ref-type="fn"}   \>ULN            1·1 (0·7--1·8)[\*\*](#cei13283-note-0012){ref-type="fn"}   
  Endostatin (ng/ml)   ≤2                                                       139 (127--151)    M1a/b                                                    135 (118--155)   Norm                                                       142 (130--154)
  \>2                  162 (148--178)[\*](#cei13283-note-0011){ref-type="fn"}   M1c               154 (143--166)                                           \>ULN            161 (146--178)                                             
  PARC (ng/ml)         ≤2                                                       75 (66--86)       M1a/b                                                    74 (60--92)      Norm                                                       76 (67--85)
  \>2                  99 (87--113)[\*\*](#cei13283-note-0012){ref-type="fn"}   M1c               90 (80--100)                                             \>ULN            103 (90--119)[\*\*](#cei13283-note-0012){ref-type="fn"}    
  Gal3BP (µg/ml)       ≤2                                                       1·7 (1·3--2·2)    M1a/b                                                    1·1 (0·8--1·6)   Norm                                                       1·5 (1·2--1·9)
  \>2                  1·8 (1·4--2·3)                                           M1c               1·9 (1·6--2·3)[\*](#cei13283-note-0011){ref-type="fn"}   \>ULN            2·1 (1·6--2·7)                                             
  CRP (µg/ml)          ≤2                                                       1·1 (0·7--1·7)    M1a/b                                                    0·8 (0·4--1·5)   Norm                                                       1·1 (0·7--1·7)
  \>2                  2·1 (1·3--3·4)[\*](#cei13283-note-0011){ref-type="fn"}   M1c               1·8 (1·3--2·6)[\*](#cei13283-note-0011){ref-type="fn"}   \>ULN            2·3 (1·4--3·8)[\*](#cei13283-note-0011){ref-type="fn"}     

Data are given as back‐transformed estimated marginal means adjusted for age and sex. \> ULN = above upper level of normal; LDH = lactate dehydrogenase; M stage = metastatic stage (AJCC cancer staging manual); OPG = osteoprotegerin; GDF15 = growth differentiation factor 15; PARC = pulmonary and activation‐regulated chemokine; Gal3BP = galectin‐3 binding‐protein/CYT‐MAA/K90/Mac‐2BP; CRP = C‐reactive protein.

*P* \< 0·05;

*P* \< 0·01 comparing non‐survivors and survivors.
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Predictors of outcome {#cei13283-sec-0010}
---------------------

We next evaluated the accuracy of the selected markers in predicting disease outcome using ROC analysis. As shown in Fig. [1](#cei13283-fig-0001){ref-type="fig"}a, all the selected markers at baseline gave good discrimination between survivors and non‐survivors, with AUC between 0·70 and 0·76. Further, all markers, except Gal3BP, displayed a symmetrical area indicating that median levels could be a reasonable cut‐off. Kaplan--Meier survival curves for all‐cause mortality, using the median to dichotomize the data, confirmed that higher levels of each marker were associated with poor prognosis. We next evaluated the prognostic value of the selected markers in multivariable Cox‐regression models. Figure [2](#cei13283-fig-0002){ref-type="fig"}a shows the univariate and multivariable analysis of clinical markers, indicating that these markers were significantly associated with all‐cause mortality, and also when put together in a multivariable model. These markers of disease severity were used in subsequent adjustment strategies. Figure [2](#cei13283-fig-0002){ref-type="fig"}b shows the univariate and multivariable analysis (i.e. adjusted for LDH levels, M‐stage and number of organs affected) for each of the suggested biomarkers. All markers were associated with all‐cause mortality in univariate analysis, with hazard ratios (HR) between 1·7 and 2·2. The association between survival and GDF15, OPG and PARC were markedly attenuated by multivariable adjustment and were no longer significantly associated with death. Endostatin and Gal3BP were also modified by adjustment but remained significantly associated with all‐cause death. Figure [2](#cei13283-fig-0002){ref-type="fig"}c shows a Cox regression model with a stepwise selection of the best clinical and biochemical variables and indicates that endostatin and LDH are the strongest predictors, followed by M‐stage.

![Survival analysis of inflammatory biomarkers during ipilimumab therapy. (a) Receiver operating curves (ROC) and diagnostic accuracy for all‐cause mortality. (b) Kaplan--Meier curves for all‐cause mortality by dichotomized levels of inflammatory markers.](CEI-197-74-g001){#cei13283-fig-0001}

![Univariate (blue circle) and multivariable (red square) Cox regression of clinical and inflammatory biomarkers as predictors of all‐cause mortality during ipilimumab therapy. (a) Clinical predictors. (b) Inflammatory biomarkers alone and after adjustment with LDH, M stage, and organs affected. (c). Stepwise model of the strongest predictors including both clinical and inflammatory markers. Hazard ratios (HR) for inflammatory markers are expressed as log‐transformed per standard deviation change in marker.](CEI-197-74-g002){#cei13283-fig-0002}

Discussion {#cei13283-sec-0011}
==========

Ipilimumab has improved survival in subgroups of patients with MM, but no biomarker is currently available for predicting treatment benefit. The present study was initiated to evaluate if biomarkers reflecting inflammation, vascular inflammation, angiogenesis and ECM remodeling could predict prognosis in patients treated with ipilimumab. Several markers reflecting different pathways correlated with indices of disease severity were consistently elevated in non‐survivors after initiation of treatment. In particular, high levels of Gal3BP and endostatin were also independently associated with poor survival in adjusted analysis, and deserve further attention as possible prognostic biomarkers in this population.

Whereas ipilimumab enhances the immune response against tumor, persistent low‐grade local and systematic immune response and inflammation could also promote tumor progression and death of patients with MM [24](#cei13283-bib-0024){ref-type="ref"}, [25](#cei13283-bib-0025){ref-type="ref"}. Several studies have revealed an association between leukocyte counts, conventional markers such as CRP and LDH and clinical outcome in MM [20](#cei13283-bib-0020){ref-type="ref"}, [21](#cei13283-bib-0021){ref-type="ref"}, [22](#cei13283-bib-0022){ref-type="ref"}, [23](#cei13283-bib-0023){ref-type="ref"}, [25](#cei13283-bib-0025){ref-type="ref"}, [26](#cei13283-bib-0026){ref-type="ref"}, [27](#cei13283-bib-0027){ref-type="ref"}, [28](#cei13283-bib-0028){ref-type="ref"}, [29](#cei13283-bib-0029){ref-type="ref"}, [30](#cei13283-bib-0030){ref-type="ref"}, [31](#cei13283-bib-0031){ref-type="ref"}. The present study supports and extends these findings by showing that biomarkers that reflect a range of inflammatory‐related pathways, including vascular inflammation, ECM remodeling/fibrosis and angiogenesis, correlate with different indices of disease severity, and are consistently up‐regulated in non‐survivors after initiation of ipilimumab. Thus, low or normal levels of OPG, GDF15, endostatin, PARC, Gal3BP and CRP in MM patients have the potential to identify patients who may benefit from such therapy. Indeed, comparing these biomarkers in multivariable analysis revealed that two of these markers, i.e. endostatin and Gal3BP, were independently associated with poor prognosis, suggesting that these markers could reflect distinct processes related to MM progression that is not necessarily reversed by ipilimumab therapy.

Endostatin is a 20‐kDa C‐terminal fragment from type XVIII collagen, generally found in epithelial and endothelial vascular basement membranes, and is an endogenous inhibitor of angiogenesis [32](#cei13283-bib-0032){ref-type="ref"}, [33](#cei13283-bib-0033){ref-type="ref"}. Endostatin blocks the proliferation and organization of endothelial cells into new blood vessels and inhibits angiogenesis and growth of both primary tumors and secondary metastasis [34](#cei13283-bib-0034){ref-type="ref"}, [35](#cei13283-bib-0035){ref-type="ref"}, [36](#cei13283-bib-0036){ref-type="ref"}, [37](#cei13283-bib-0037){ref-type="ref"}, [38](#cei13283-bib-0038){ref-type="ref"}. Interestingly, endostatin seems to be predominantly linked to angiogenesis arriving from pathogenic sources such as tumors, while processes such as wound healing are not affected [39](#cei13283-bib-0039){ref-type="ref"}, and endostatin has been suggested as adjuvant therapy in various malignancies. High expression of endostatin in tumor tissue may also indicate poor prognosis, probably reflecting substantial tumor burden and active stromal remodeling [40](#cei13283-bib-0040){ref-type="ref"}. Thus, the association between high endostatin levels, the number of organs affected and poor outcome in our study could potentially reflect an enhanced compensatory response to limit angiogenesis as well as ECM remodeling. Our finding is supported by previous studies demonstrating that high circulating endostatin levels are associated with poor outcome or an aggressive phenotype in a variety of malignancies [40](#cei13283-bib-0040){ref-type="ref"}, [41](#cei13283-bib-0041){ref-type="ref"}, [42](#cei13283-bib-0042){ref-type="ref"}, [43](#cei13283-bib-0043){ref-type="ref"}, [44](#cei13283-bib-0044){ref-type="ref"}. It is also possible that endostatin could counteract the effect of ipilimumab by attenuating the infiltration of activated T cells into the tumor, but this hypothesis needs to be proved in future studies.

Galectins are a family of beta‐galactoside‐binding proteins implicated in modulating cell--cell and cell--matrix interactions, angiogenesis and apoptosis [45](#cei13283-bib-0045){ref-type="ref"}. Galectin‐3‐binding protein is a glycoprotein expressed in normal cells, but elevated circulating levels have been demonstrated in multiple cancers [46](#cei13283-bib-0046){ref-type="ref"}, [47](#cei13283-bib-0047){ref-type="ref"}, [48](#cei13283-bib-0048){ref-type="ref"}, [49](#cei13283-bib-0049){ref-type="ref"}, [50](#cei13283-bib-0050){ref-type="ref"}, [51](#cei13283-bib-0051){ref-type="ref"}, [52](#cei13283-bib-0052){ref-type="ref"} including melanoma [53](#cei13283-bib-0053){ref-type="ref"}. The role of Gal3BP in cancer prognosis seems equivocal with both negative and positive influences on the prognosis of various cancers, but high levels are mainly associated with shorter survival, disease progression [54](#cei13283-bib-0054){ref-type="ref"}, [55](#cei13283-bib-0055){ref-type="ref"} and reduced response to chemotherapy. Our finding of consistently increased Gal3BP following immunotherapy supports a previous study showing an association between high levels and clinical outcome in melanoma patients [45](#cei13283-bib-0045){ref-type="ref"}, [54](#cei13283-bib-0054){ref-type="ref"}, but so far there are no data on Gal3BP or endostatin as biomarkers of ipilimumab therapy. Mechanisms underlying over‐expression of Gal3BP in cancer is not fully understood, but its association with multiple forms of cancer could be related to the multidomain nature of the protein and ability to bind different ligands in different tumor tissues.

As this was not a placebo‐controlled trial, it is hard to conclude if the association of high levels of endostatin and Gal3BP was a marker of treatment efficiency or related to disease progression independently of therapy. At present, we can only suggest that high levels of these markers reflect disease progression during ipilimumab therapy. However, the mechanisms for this association seem to differ between the two markers. Thus, as endostatin has been shown to have anti‐angiogenetic properties with potential attenuating effects on carcinogenesis, the high levels may reflect counteracting mechanisms in a tumor with a large pro‐angiogenetic potential and therefore poor prognosis. Conversely, Gal3BP may reflect activation of pathways that promote maladaptive ECM remodeling which could enhance tumor progression. Indeed, a recent study in melanoma shows that the combination of ipilimumab with the vascular endothelial growth factor (VEGF)‐A blocking antibody bevacizumab induced increased antibody response to galectin‐3, and this response was associated with improved prognosis [56](#cei13283-bib-0056){ref-type="ref"}. No such antibody response was seen during PD‐1 inhibition.

To the best of our knowledge, endostatin or GAL3BP have not been reported as markers for treatment efficacy during immunotherapy in melanoma or other cancers. However, a galectin 3 inhibitor, in combination with ipilimumab or PD‐1 inhibition, is being currently evaluated for the treatment of patients with metastatic melanoma [57](#cei13283-bib-0057){ref-type="ref"} underscoring that galectin 3 or its marker Gal3BP (as well as endostatin) could be part of a panel of biomarkers that predicts the outcome for immunotherapy in melanoma. Our data suggest endostatin and Gal3BP as potential prognostic biomarkers for ipilimumab in MM. The study does not provide mechanistic insight into the relationship between biomarkers and induced responses, but it is tempting to speculate that the correlation with disease severity and consistent up‐regulation of multiple inflammatory‐related markers in non‐survivors could reflect that these patients have progressed too far to respond to ipilimumab. Analysis of pretreatment blood samples could enable the identification of possible biomarkers that could help in making treatment decisions in patients with MM. However, the number of included patients is small, and the results need to be confirmed in a larger study. Moreover, short‐term observation, as in the present study (2 years), will 'select' for biomarkers that predict short‐term progression rather than a favorable clinical outcome. Accordingly, larger studies with long‐term follow‐up are needed to evaluate these molecules as potential biomarkers for long‐term survival following ipilimumab therapy. The strength is, however, that this is a prospective study and the data are derived from a 'real‐world' patient cohort, and the selected candidates (i.e. endostatin and Gal3BP) should be further investigated in MM during various forms of therapeutic approaches.
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